Form 4: Orchestra BioMed Director Acquires Stock Options, RSUs

David Pacitti, a Director at Orchestra BioMed Holdings, Inc., acquired restricted stock units and stock options on June 23, 2026, as part of his compensation.

Summary

• David Pacitti, a Director at Orchestra BioMed Holdings, Inc. (OBIO), was granted 17,327 Restricted Stock Units (RSUs) on June 23, 2026. These RSUs vest one year from the grant date, contingent on continued service.
• On the same date, 3,784 shares of common stock were withheld by the issuer to cover tax obligations related to the vesting of RSUs. No market sales occurred for this purpose.
• Additionally, Pacitti was granted stock options to purchase 21,277 shares of common stock at an exercise price of $4.04, with a vesting period of one year from the grant date, also subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting standard compensation practices for a company director rather than significant new financial performance or strategic shifts.

Positives

• Director compensation through equity awards (RSUs and stock options) indicates alignment with long-term company performance.
• The grant of stock options suggests management's belief in future stock price appreciation.
• The withholding of shares for tax obligations, rather than market sales, suggests a commitment to holding shares.

Negatives

• The withholding of shares for tax obligations, while standard, reduces the net number of shares received by the director.
• The vesting period for both RSUs and stock options means the full benefit is deferred, subject to continued employment.

Risks

• The value of the RSUs and stock options is subject to the future performance of Orchestra BioMed's stock price.
• Continued service is a condition for vesting, meaning any departure before the vesting date would result in forfeiture of these awards.

Future Outlook

The vesting of RSUs and stock options is contingent on the reporting person's continuous service through the one-year anniversary of the grant date, which is June 23, 2027.

Industry Context

StockSavvy.ai notes that the issuance of RSUs and stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize long-term commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The equity awards align director incentives with long-term company performance, potentially benefiting shareholders if the stock price increases.
• Employees: The transaction does not directly impact employees, but it reflects standard compensation practices within the company.
• Management: The director receives compensation in the form of equity, which is a common incentive.

Next Steps

• Vesting of RSUs on June 23, 2027, subject to continued service.
• Vesting of stock options on June 23, 2027, subject to continued service.

Key Dates

Keywords

Orchestra BioMed, OBIO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSUs, Director Compensation, Beneficial Ownership, Securities Exchange Act